A groundbreaking study led by the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), has demonstrated the protective potential of three distinct HIV antibodies in preventing simian-HIV (SHIV) acquisition in monkeys. The study, published in Science Translational Medicine, aimed to provide crucial insights for the development of a preventive HIV vaccine for humans.
The antibodies under investigation targeted the fusion peptide, a critical site on the surface protein of HIV that facilitates the virus’s fusion with and entry into host cells. These antibodies included a human broadly neutralizing antibody named VRC34.01 and two antibodies isolated from previously vaccinated rhesus macaques, a species with immune systems similar to humans. The ability of these antibodies to neutralize diverse strains of HIV in vitro had been established, prompting further exploration in an in vivo setting.
VRC34.01, a fusion peptide-directed human antibody, was isolated from an individual living with HIV who generously provided blood samples for research. Additionally, two antibodies were derived from rhesus macaques that had received a vaccine regimen designed to stimulate the production of fusion peptide-directed antibodies. The study aimed to validate the fusion peptide as a viable target for the development of an effective human HIV vaccine, with SHIV challenge experiments in rhesus macaques serving as a widely accepted animal model for evaluating the efficacy of HIV antibodies and vaccines.
The experimental design involved four groups of rhesus macaques, each receiving a single intravenous infusion of one type of antibody: either a 2.5 or 10 mg/kg dose of VRC34.01, or one of the two vaccine-elicited rhesus macaque antibodies. A control group received a placebo infusion. To assess the protective effect of the antibodies, the monkeys were challenged with a SHIV strain known to be susceptible to fusion peptide-directed antibodies five days after infusion.
Remarkably, all monkeys in the placebo group acquired SHIV following the challenge. In contrast, those that received VRC34.01 infusions exhibited a significant level of protection, with none of the monkeys receiving the higher 10 mg/kg dose acquiring SHIV, and only 25% of those receiving the 2.5 mg/kg dose becoming infected. Similarly, monkeys that received the vaccine-elicited rhesus macaque antibodies demonstrated noteworthy protection. Specifically, none of the monkeys receiving the DFPH-a.15 antibody acquired SHIV, while 25% of those receiving the DF1W-a.01 antibody were infected.
The concentration of antibodies in the blood of animals that received the DFPH-a.15 antibody declined over time. To assess the impact of this decrease, these animals were re-challenged 30 days later. Alarmingly, half of them acquired SHIV, highlighting the importance of maintaining adequate antibody levels for sustained protection.
The study concluded that all three antibodies provided statistically significant protection against SHIV, and this protection exhibited a dose-dependent relationship, with higher antibody concentrations correlating with increased efficacy. The findings offer proof-of-concept for the idea that fusion peptide-directed antibodies can confer protection against SHIV. Importantly, the study suggests that an effective HIV vaccine targeting the fusion peptide may need to generate multiple varieties of fusion peptide-directed antibodies to address the vast diversity of circulating HIV variants.
This research represents a significant step forward in understanding the potential of fusion peptide-directed antibodies in HIV prevention. The results not only support further exploration of vaccine concepts targeting the fusion peptide but also emphasize the necessity of developing strategies that account for the diverse array of HIV variants to ensure a broadly effective preventive vaccine.
News Reference
National Institute of Health
